19 studies found for:    golimumab, ulcerative colitis
Show Display Options
Rank Status Study
1 Active, not recruiting A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Intervention: Drug: Golimumab
2 Unknown  Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab
Condition: Ulcerative Colitis
Intervention: Drug: Golimumab
3 Completed Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
Condition: Ulcerative Colitis
Interventions: Drug: Golimumab Prefilled Syringe;   Drug: Golimumab Smartject™ Device
4 Recruiting Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission
Condition: Colitis, Ulcerative
Intervention: Drug: Golimumab
5 Recruiting Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention:
6 Completed Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
Condition: Ulcerative Colitis
Intervention: Drug: Golimumab
7 Completed A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.
Condition: Colitis, Ulcerative
Interventions: Drug: Golimumab;   Other: Placebo
8 Not yet recruiting Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - (TARGET)
Condition: ULCERATIVE COLITIS
Intervention: Drug: GOLIMUMAB
9 Terminated
Has Results
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Other: Placebo;   Drug: Golimumab 1 mg per kg;   Drug: Golimumab 2 mg per kg;   Drug: Golimumab 4 mg per kg
10 Completed
Has Results
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Biological: Placebo;   Biological: Golimumab 100 mg;   Biological: Golimumab 200 mg;   Biological: Golimumab 400 mg;   Biological: Golimumab 50 mg
11 Completed A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Intervention: Biological: Golimumab
12 Recruiting Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab
Condition: Ulcerative Colitis
Intervention:
13 Recruiting Correlation of Soluble ST2 With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Condition: Colitis, Ulcerative
Intervention: Biological: Golimumab
14 Completed
Has Results
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Biological: Placebo;   Biological: Golimumab 50 mg;   Biological: Golimumab 100 mg;   Biological: Golimumab 200 mg
15 Not yet recruiting An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention:
16 Not yet recruiting Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
Condition: Ulcerative Colitis
Intervention: Other: patients receiving biopsies
17 Not yet recruiting Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
Condition: Colitis
Intervention: Drug: Golimumab (GLM)
18 Recruiting A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Condition: Hepatosplenic T-Cell Lymphoma
Intervention: Biological: Collection of samples
19 Recruiting Entyvio (Vedolizumab) Long Term Safety Study
Condition: Ulcerative Colitis and Crohn's Disease
Interventions: Drug: Vedolizumab;   Other: Other Biologic Agents

Indicates status has not been verified in more than two years